FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Sonnet BioTherapeutics Holdings, Inc. Stock AnalysisComprehensive stock analysis for Sonnet BioTherapeutics Holdings, Inc. (SONN) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisSONN
SONN
Sonnet BioTherapeutics Holdings, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
SONN
Home🔹Stocks🔹Sonnet BioTherapeutics Holdings, Inc.

Sonnet BioTherapeutics Holdings, Inc.

SONN•NASDAQ

Sonnet BioTherapeutics Holdings, Inc.

SONN•NASDAQ
Market cap
$8.43M
Sentiment

Your view on SONN

Mkt Cap
$8.43M
Sentiment
Your view
SONN
Sonnet BioTherapeutics Holdings, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
SONN
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Sonnet BioTherapeutics Holdings, Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
Raghu Rao
Headquarters
100 Overlook Center, Princeton, NJ, US
Industry
Biotechnology
Sector
Healthcare
CEO
Raghu Rao
Headquarters
100 Overlook Center, Princeton, NJ, US
Description

Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6 for chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy. It has a license agreement with New Life Therapeutics PTE, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin 6. Sonnet BioTherapeutics Holdings, Inc. is based in Princeton, New Jersey.

Infographics

Visual summary of the business at a glance.

FRC Research

Media

Videos and interviews covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News